Friday, May 17, 2024
(8:15 AM EST – 4:00 PM EST)
Experience in-person presentations by our expert presenters and join interactive working sessions.
Event Overview:
This full-day, educational event is organized for and by members of the Alimentiv Translational Research Consortium (ATRC) to understand the role of combination therapies in IBD and what can be learned from other indications who were early adopters of combination therapy.
The Symposium will bring together key stakeholders including gastroenterologists, basic & translational scientists, clinical pharmacologists, trialists and industry sponsors.
Location: The Westin Washington, D.C. City Center
Address: 1400 M Street NW, Washington, DC, USA, 20005
Symposium: Friday, May 17, 2024 (8:15 AM – 4:00 PM EST)
Reception: Immediately following the symposium
| 7:45 AM EST | Registration & Continental Breakfast |
| 8:15 AM EST | Welcome & Introductions |
|
Session 1: Clinical Efficacy and Safety on Combination Therapy Chair: Vipul Jairath MBChB, DPhil, MRCP, FRCPC (Western University/Alimentiv) |
|
| 8:30 AM |
State of the art: Combination Therapy in IBD - how did we get here and where are we going
Jean-Frederic Colombel, MD (Icahn School of Medicine at Mount Sinai, USA) |
| 9:00 AM |
State of the art: Combination Therapy in Rheumatology - how did we get here and where are we going
Arthur Kavanaugh, MD (University of California San Diego, USA) |
| 9:30 AM | Panel discussion |
| 9:55 AM | Break |
|
Session 2: Clinical Pharmacology & Translational Medicine of Combination Therapy Chair: Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai, USA) |
|
| 10:15 AM |
Impact of combination therapy on mucosal and systemic immune system
Dylan Richards, PhD (Janssen, USA) |
| 10:40 AM |
Mechanistic vs. opportunistic approach to combination therapies
Saurabh Mehandru, MD (Icahn School of Medicine at Mount Sinai, USA) |
| 11:05 AM |
Combo Therapy: Considerations from the Clin Pharm Perspective
Niels Vande Casteele, PharmD, PhD (University of California San Diego / Alimentiv & AcelaBio, USA) |
| 11:30 AM | Panel Discussion |
| 11:55 AM | Lunch |
|
Session 3: Drug Design & Development Chair: Vipul Jairath MBChB, DPhil, MRCP, FRCPC (Western University/Alimentiv) |
|
| 12:55 PM |
Challenges and opportunities when developing bi-specific antibodies or antibody constructs
Jackie Benson, PhD (Sorriso Pharmaceuticals, USA) |
| 1:20 PM |
Clinical trial design considerations when testing combination therapies
Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai, USA) |
| 1:45 PM | Panel discussion |
| 2:10 PM | Break |
|
Session 4: Breakout Session Chair: Niels Vande Casteele, PharmD, PhD (UC San Diego / Alimentiv & AcelaBio, USA) |
|
| 2:25 PM | Instructions for breakout groups |
| 2:30 PM | Breakout groups |
| 3:10 PM | Breakout group presentations & general discussion |
| 3:50 PM | Summary and wrap-up |
| 4:00 PM | Adjourn & reception to follow |
